Beinaglutide

贝那鲁肽

Report date: 2023/08/04 14:28:56

Base Information

Drug NameBeinaglutide
Drug Alias Namerh-YST活性多肽rh-YSThGLP-1重组人胰高血糖素类多肽-1(7-36)谊生泰 +[8] 
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsOverweightObesityHyperglycemia +[5] 
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryMainland China
Original Approved Date2016/12/13
Country/TerritoryGermanyMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShanghai Benemae Pharmaceutical Co
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Benemae Pharmaceutical Co
Inactive CompaniesLudwig Maximilians University Of Munich
Active IndicationsOverweightObesityDiabetes Mellitus, Type 2 +[4] 
Inactive IndicationsHyperglycemia

Other Information

ATC CodeA10BJ
Related LinksN/A